Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Argenx and Bird Rock Bio Seek To Differentiate Early With Anti-IL6 RA Drug

This article was originally published in Scrip

Executive Summary

Belgian biotech Argenx N.V. is looking to low and infrequent dosing to carve out a place for its novel anti-inflammatory in rheumatoid arthritis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register